N-2-Methylpropenylthioacetamid | 37109-54-9

• 分子结构分类: 有机化合物 - 有机硫化合物 - 硫代酰胺
• 英文名称: N-2-Methylpropenylthioacetamid
• 英文别名: N-(2-Methyl-1-propenyl)-thioacetamid；N-(2-methylprop-1-enyl)ethanethioamide
• CAS: 37109-54-9
• 化学式: C₆H₁₁NS
• mdl: MFCD19218452
• 分子量: 129.226
• InChiKey: CZCGYFSAPODYTJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  8
• 可旋转键数：
  1
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  44.1
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  2,4,4-trimethylthiazolidine 以 乙腈 为溶剂， 生成 N-2-Methylpropenylthioacetamid
  参考文献：
  名称：

  光致反应—LXXIX：2-噻唑啉的光化学

  摘要：

  在2537Å的光照射下，2-烷基-2-噻唑啉（1）重排为主要途径的N-烯基硫酰胺（2和3），并碎裂为次要的腈和环硫化物。为中间形成价键异构体N-硫代酰基氮丙啶提供了证据，然后将其光化学转化为N-烯基硫代酰胺。

  DOI：

  10.1016/0040-4020(75)80164-5

文献信息

• [EN] NEW FYN AND VEGFR2 KINASE INHIBITORS<br/>[FR] NOUVEAUX INHIBITEURS DE KINASES FYN ET VEGFR2
  申请人：ROTTAPHARM BIOTECH SRL

  公开号：WO2021115560A1

  公开（公告）日：2021-06-17

  The invention relates to a N-phenylcarbamoyl compound of Formula (I) or a pharmaceutically acceptable salt thereof for use in the inhibition of at least one of tyrosine kinase selected from Fyn and VEGFR2 in the treatment of diseases and disorders involved with one or both kinases. (Formula)

  该发明涉及一种化合物N-苯基甲酰胺（I）的使用或其在治疗涉及Fyn和VEGFR2中至少一种酪氨酸激酶抑制剂中的药用盐，用于治疗与这两种激酶中至少一种相关的疾病和疾病。
• Pyran-Spirocyclic Piperidine Amides as Modulators of Ion Channels
  申请人：Vertexs Pharmaceuticals Incorporated

  公开号：US20150005304A1

  公开（公告）日：2015-01-01

  The invention relates to pyran spirocyclic piperidine amide compounds useful as inhibitors of ion channels. The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various disorders.

  本发明涉及一种吡喃螺环哌啶酰胺化合物，可用作离子通道的抑制剂。本发明还提供了包含本发明化合物的药学上可接受的组合物，并提供了使用这些组合物治疗各种疾病的方法。
• Heteroaryl Substituted Pyrrolo[2,3-B] Pyridines And Pyrrolo[2,3-B] Pyrimidines As Janus Kinase Inhibitors
  申请人：Incyte Corporation

  公开号：US20150238492A1

  公开（公告）日：2015-08-27

  The present invention provides heteroaryl substituted pyrrolo[2,3-b]pyridines and heteroaryl substituted pyrrolo[2,3-b]pyrimidines that modulate the activity of Janus kinases and are useful in the treatment of diseases related to activity of Janus kinases including, for example, immune-related diseases, skin disorders, myeloid proliferative disorders, cancer, and other diseases.

  本发明提供了杂环芳基取代的吡咯[2,3-b]吡啶和杂环芳基取代的吡咯[2,3-b]嘧啶，它们可以调节Janus激酶的活性，并且在治疗与Janus激酶活性相关的疾病方面非常有用，例如免疫相关疾病、皮肤疾病、骨髓增生性疾病、癌症和其他疾病。
• OXAZOLIDONE COMPOUND, PREPARING METHOD AND APPLICATION THEREOF
  申请人：SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES

  公开号：US20150361091A1

  公开（公告）日：2015-12-17

  The present invention relates to the field of a pharmaceutical compound, and more specifically, relates to a new oxazolidone compound, an enantiomer, a diastereoisomer and a raceme thereof, and a mixture thereof, and a pharmaceutically acceptable salt thereof, a preparation method thereof, an application thereof as a bioactive substance in a drug. The compound in the present invention has strong anticoagulant activity, does not affect the activity of thrombin, and can reduce the risk of hemorrhage. A pharmacokinetics experiment shows that the compound in the present invention further has good metabolic characteristics, and has a far better oral bioavailability than a positive contrastive agent rivaroxaban.

  本发明涉及制药化合物领域，更具体地涉及一种新的噁唑烷化合物，其对映异构体、二对映异构体和混合物，以及其药学上可接受的盐、制备方法及其在药物中作为生物活性物质的应用。本发明中的化合物具有强烈的抗凝血活性，不影响凝血酶的活性，并能降低出血风险。药代动力学实验表明，本发明中的化合物还具有良好的代谢特性，并且具有比阳性对照剂利伐沙班更好的口服生物利用度。
• LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS FOR THE TREATMENT OF CONDITIONS OR DISEASES OF THE EYE
  申请人：Hutchinson John Howard

  公开号：US20130253019A1

  公开（公告）日：2013-09-26

  Described herein is the use of LPA1 antagonists in the treatment or prevention of diseases or conditions of the eye of a mammal. Also described are pharmaceutical compositions that include at least one LPA1 antagonist.